Medicines Co
Change company Symbol lookup
Select an option...
MDCO Medicines Co
LOTE Lot78 Inc
GIXEF Geologix Explorations Inc
GILXF Gitennes Exploration Inc
GIKLY Grifols SA
GIGNY Genting Singapore Ltd
GIGNF Genting Singapore Ltd
GIDYL GI Dynamics Inc
GHST Ghst International Inc
GHRI Goliath Resources Inc
Go

Health Care : Pharmaceuticals | Small Cap BlendCompany profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

Postmarket

Last Trade
Delayed
$36.59
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$36.59
Day's Change
-0.85 (-2.27%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
37.75
Day's Low
35.82
Volume
(Above Average)
Volume:
898,927

10-day average volume:
806,450
898,927

Display:

Providers:

UpdateCancel
5 providers
May 07, 2018
The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of Bad Cholesterol (Atherogenic Lipoproteins) Linked to Heart Attack and Stroke

--Inclisiran drove sustained lowering of key atherogenic lipoproteins - non-HDL-C, ApoB, VLDL-C and Lp(a) --Pre-specified analysis of ORION-1 Phase II study featured in late-breaking session at 86th Annual European Atherosclerosis Society Congress (BusinessWire)

April 30, 2018
The Medicines Company Presents New Data at the National Lipid Association Scientific Sessions

The Medicines Company (NASDAQ:MDCO) presented important new data and analyses from the ORION development program for inclisiran at the National Lipid Association (NLA) 2018 Scientific Sessions held in Las Vegas, NV. Multiple...(BusinessWire)

April 25, 2018
The Medicines Company Reports First-Quarter 2018 Results

The Medicines Company (NASDAQ: MDCO) today reported its financial results for the first quarter ended March 31, 2018. "During the first quarter of 2018, The Medicines Company continued to demonstrate strong clinical and operational...(BusinessWire)

April 19, 2018
The Medicines Company to Announce First-Quarter 2018 Financial Results on April 25

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, April 25, 2018, at 8:30 a.m., Eastern Time, to discuss first-quarter 2018 financial results and operational developments. (BusinessWire)

March 29, 2018
Recro Pharma Announces Commercial Team Additions

Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the expansion of its team through the appointment of seven new...(Globe Newswire)

March 28, 2018
The Medicines Company Announces Chief Financial Officer Transition

The Medicines Company (NASDAQ: MDCO) today announced the appointment of Christopher Visioli as Chief Financial Officer and Treasurer of the Company, effective immediately. Mr. Visioli succeeds William B. O'Connor, who is...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2018 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2018. All rights reserved.